Pfizer Limited has informed the Exchange regarding a press release dated August 11, 2025, titled "Pfizer Launches 20-valent Pneumococcal Conjugate Vaccine (PCV20) for Adults in India, Offering Broad Protection Against Pneumococcal Disease".
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pfizer Limited has launched its 20-valent Pneumococcal Conjugate Vaccine (PCV20) for adults in India on August 11, 2025. The vaccine protects against 20 serotypes of pneumococcal disease in a single dose and is approved for adults aged 18 years and older. It covers more serotypes than any other conjugate vaccine previously available in India. The product targets high-risk groups including adults over 50 years and those with chronic conditions such as asthma, COPD, chronic kidney disease, and diabetes. The launch strengthens Pfizer's preventive healthcare portfolio and builds on its 25-year legacy in pneumococcal vaccine innovation.
This is a positive development for Pfizer as it expands the company's adult immunization offerings in India and could drive incremental revenue in the preventive vaccines segment. No immediate financial impact figures were disclosed in the filing.